Skip to main content
Top
Published in: Acta Diabetologica 5/2019

01-05-2019 | Prediabetes | Perspectives

The STOP DIABETES study: when prevention works

Authors: Aldo Bonaventura, Fabrizio Montecucco

Published in: Acta Diabetologica | Issue 5/2019

Login to get access

Abstract

Although many drugs are now available, a large effort is still needed to prevent diabetes. The STOP DIABETES study evaluated individuals at risk for type 2 diabetes (T2D) by a 2-h 75-g oral glucose tolerance test (OGTT). Based on the three main defective physiological responses, subjects were stratified as at low, intermediate, or high risk, and treated accordingly with lifestyle modifications and drugs. Participants at intermediate and high risk experienced the greatest reduction of T2D conversion. Interestingly, a group of individuals developing T2D presented a normal glucose tolerance at baseline, but a 1-h plasma glucose concentration > 155 mg/dL. These results are critical as prediabetes can increase the incidence of cardiovascular disease. Considering the timeframe between the first defects in glucose metabolism and the manifestation of diabetes complications, the effort to tackle the glycemic impairment as soon as possible represents an outstanding task to reduce the incidence of diabetes. Ideally, the earlier glycemic alterations are recognized, the lesser armamentarium needs to be used, and the lower is the expense in terms of drugs, complications, and related events and costs. Finally, a wealth of studies clearly demonstrated the importance of 1-h plasma glucose concentration, which has been proposed as an adjunctive diagnostic tool to detect prediabetes earlier. In conclusion, by an OGTT, a lot of individuals at risk for T2D may be detected when the central role for the 1-h plasma glucose concentration is also considered. Consequently, these subjects would be treated early and with less drugs and delay T2D complications.
Literature
14.
go back to reference Abdul-Ghani MA, Puckett C, Triplitt C et al (2015) Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab 17(3):268–275. https://doi.org/10.1111/dom.12417CrossRefPubMedPubMedCentral Abdul-Ghani MA, Puckett C, Triplitt C et al (2015) Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab 17(3):268–275. https://​doi.​org/​10.​1111/​dom.​12417CrossRefPubMedPubMedCentral
15.
go back to reference Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med J Br Diabet Assoc 19(9):708–723CrossRef Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med J Br Diabet Assoc 19(9):708–723CrossRef
23.
go back to reference Manco M, Panunzi S, Macfarlane DP et al (2010) One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33(9):2090–2097. https://doi.org/10.2337/dc09-2261CrossRefPubMedPubMedCentral Manco M, Panunzi S, Macfarlane DP et al (2010) One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33(9):2090–2097. https://​doi.​org/​10.​2337/​dc09-2261CrossRefPubMedPubMedCentral
28.
go back to reference Fiorentino TV, Succurro E, Andreozzi F, Sciacqua A, Perticone F, Sesti G (2019) One-hour post-load hyperglycemia combined with HbA1c identifies individuals with higher risk of cardiovascular diseases: cross-sectional data from the CATAMERI study. Diabetes Metab Res Rev 35(2):e3096. https://doi.org/10.1002/dmrr.3096CrossRefPubMed Fiorentino TV, Succurro E, Andreozzi F, Sciacqua A, Perticone F, Sesti G (2019) One-hour post-load hyperglycemia combined with HbA1c identifies individuals with higher risk of cardiovascular diseases: cross-sectional data from the CATAMERI study. Diabetes Metab Res Rev 35(2):e3096. https://​doi.​org/​10.​1002/​dmrr.​3096CrossRefPubMed
30.
go back to reference Liu K, Dyer AR, Vu TH et al (2005) One-hour postload plasma glucose in middle age and Medicare expenditures in older age among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry. Diabetes Care 28(5):1057–1062CrossRef Liu K, Dyer AR, Vu TH et al (2005) One-hour postload plasma glucose in middle age and Medicare expenditures in older age among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry. Diabetes Care 28(5):1057–1062CrossRef
32.
go back to reference UK Prospective Diabetes Study 16 (1995) Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 44(11):1249–1258CrossRef UK Prospective Diabetes Study 16 (1995) Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 44(11):1249–1258CrossRef
Metadata
Title
The STOP DIABETES study: when prevention works
Authors
Aldo Bonaventura
Fabrizio Montecucco
Publication date
01-05-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01309-6

Other articles of this Issue 5/2019

Acta Diabetologica 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.